



Pharmacy and Therapeutics Committee

The purpose of the P&T Committee is to evaluate available evidence regarding the relative safety and efficacy or effectiveness of prescription drugs within a class or classes, and to make recommendations to PharmPix and its clients to create and manage formularies. In its evaluation, the P&T reviews the most current available data from well-designed studies, clinical guidelines and recommendations of recognized medical organizations.

Our P&T Committee is appointed by PharmPix and made up of board-certified specialists and clinical pharmacists who are experts in diseases, drugs and treatment protocols.

The objectives of this committee:

- a) To evaluate, analyze and recommend treatment protocols and procedures for the timely use of and access to both formulary and non-formulary drug products at least annually.
- b) To establish procedures to evaluate evidence-based reviews of prescription drug classes to assist in the formation of recommendations to PharmPix and its clients' formularies.
- c) To consider and recommend action on independent evidence-based reviews of drug classes. This review must consider safety and efficacy or effectiveness available at the time of the review. All analysis, evidence and references brought to the committee by PharmPix's formulary management pharmacists for review shall be the result of a rigorous assessment of the scientific evidence.
- d) Recommendations made by the P&T Committee will be based only on clinical evidence, not on economic considerations. The cost and economic impact analysis will be performed by PharmPix's formulary management personnel.

Based on the clinical advantages or disadvantages, the P&T will categorize the drugs into one of the categories below:

- **F:** On formulary, no restrictions
- **PA:** On formulary with prior authorization criteria
- **ST:** On formulary with step therapy criteria
- **MD:** On formulary, reserved for specific provider specialties
- **QL:** On formulary with a specific quantity limit
- **AGE:** On formulary, reserved for specific age groups
- **M:** May be available
- **NF:** Not on formulary



If the drug is categorized as **F, PA, ST, MD, QL or AGE**, the medication will be added to the formulary regardless of the economic impact.

If the drug is categorized as **NF**, the medication will not be added to the formulary.

If the drug is categorized as **M**, PharmPix or the client's formulary management team will make the decision based on economic considerations, such as pharmacoeconomic studies.

- e) Identify the most clinically effective ways to perform utilization management strategies such as prior authorization, step therapy and regimen optimization, and recommend them.
- f) Develop protocols and procedures for the use of and access to non-formulary drug products.
- g) Establish policies and procedures to educate and inform health care providers about drug products, usage and committee decisions.
- h) Review the drug formularies and therapeutic classes at least annually.
- i) Review utilization management programs annually.
- j) Support educational programs promoting appropriate drug use.

If you have any questions or wish to have more information regarding this document, you can call us at **787-522-5252 EXT.219**. Our pharmacists will help you.